相关临床试验
11
7 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
N/A
进行中（未招募）
4
36.4%
尚未招募
3
27.3%
终止
1
9.1%
Unknown
3
27.3%
暂无批准数据
- Longitude Health announced that all five governing member health systems will serve as design and development partners for Longitude Cell and Gene Therapy (Longitude CGT). - The five systems—Michigan Medicine, Novant Health, Baylor Scott & White Health, Memorial Hermann Health System, and Providence—will contribute clinical, operational, financial, and technical expertise. - Longitude CGT aims to reduce administrative burden and improve patient access by addressing the operational, financial, and reimbursement complexity of cell and gene therapy delivery. - The initiative seeks to build a scalable, replicable model enabling delivery of advanced therapies beyond tertiary care centers.
- UPMC Enterprises has led an $18.25 million Series B1 funding round for Carta Healthcare, with participation from multiple strategic healthcare investors including MemorialCare Innovation Fund and Rex Health Ventures. - Carta Healthcare's AI-powered platform transforms clinical data abstraction by converting structured and unstructured healthcare data into standardized datasets, enabling more informed treatment decisions and improved patient outcomes. - The investment will accelerate Carta's expansion in the life sciences market, leveraging technology acquired from Realyze Intelligence to enhance clinical trial matching capabilities and streamline data-intensive healthcare processes.
